Triana Biomedicines, a Boston, MA-based biotechnology company, raised $110M in Series A funding.
The round was led by Lightspeed Venture Partners with participation from Pfizer Ventures, Surveyor Capital and Logos Capital.
The company intends to use the funds to expand operations and development efforts.
Triana Biomedicines is building a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Its drug discovery engine is powered by high- resolution structural insights, AI and computational tools, and bespoke chemical libraries. The target first and rational approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets.
The company is led by Dr. Patrick Trojer, President & CEO, Dr. Jesse Chen, CTO and co-founder, Dr. Jean-Christophe Harmange, CSO, and Dr. Kathleen Seyb, SVP of Biology.